

**Supplementary table 1** Baseline characteristics of responders and non-responders of the COVID-19-specific survey during the first and second wave of the COVID-19 pandemic, i.e., April 2020 and November 2020, respectively.

	First wave				Second wave			
	Responders (n=1106, 69.3%)		Non-responders (n=489, 30.7%)		Responders (n=822, 50.9%)		Non-responders (n=792, 49.1%)	
<b>Patient characteristics</b>								
Age in years, mean (range)	56	24-82	55	27-92	57	29-83	55	24-92
Sex, No. (%)								
Female	1100	99.5	487	99.6	819	99.6	788	99.5
Male	6	0.5	2	0.4	3	0.4	4	0.5
Body Mass Index <sup>1</sup> , mean (SD)	26.1	4.7	26.4	5.1	26.1	4.7	26.3	4.9
Missing, No. (%)	11	1.0	42	8.6	45	5.5	72	9.1
Highest educational level								
Primary or (post-)secondary school	488	44.1	225	46.0	339	41.2	349	44.1
College, graduate or professional degree	609	55.1	222	45.4	439	53.5	372	47.0
Unknown	9	0.8	42	8.6	44	5.4	71	9.0
Current living situation								
With partner and/or child(ren)	-	-	-	-	647	78.8	-	-
Alone/other	-	-	-	-	175	21.3	-	-
Follow-up time in months, median (range)	29	1-78	32	1-78	33	1-85	37	1-85
<b>Tumor characteristics</b>								
Pathological T stadium, No. (%)								
0 + In situ (IS)	173	15.6	91	18.6	121	14.7	134	16.9
I	641	58.0	264	54.0	442	53.8	416	52.5
II-IV	238	21.5	112	22.9	178	21.6	171	21.6
X + unknown	54	4.9	22	4.5	81	9.9	71	9.0
<b>Treatment characteristics</b>								
Type of breast surgery								
Breast conserving therapy	863	78.0	393	80.4	619	75.3	582	73.5
Mastectomy ± delayed reconstruction	106	9.6	39	8.0	69	8.4	76	9.6
Mastectomy with direct breast reconstruction	109	9.9	46	9.4	69	8.4	84	10.6
None	20	1.8	9	1.8	14	1.7	13	1.6
Unknown	8	0.7	2	0.4	51	6.2	37	4.7
Systemic therapy <sup>2</sup>								
No systemic therapy	410	37.1	172	35.2	278	33.8	282	35.6
Chemotherapy	100	9.0	53	10.8	77	9.4	72	9.1
Endocrine therapy	201	18.2	99	20.2	155	18.9	130	16.4
Immunotherapy	0	0.0	1	0.2	0	0.0	1	0.1
Combination of above <sup>3</sup>	387	35.0	162	33.1	261	31.8	270	34.1
Unknown	8	0.7	2	0.4	51	6.2	37	4.7
Radiation therapy								
Yes	993	89.8	438	89.6	702	85.4	672	84.8
None	77	7.0	38	7.8	47	5.7	62	7.8
Unknown	36	3.3	13	2.7	73	8.9	58	7.3
Currently receiving breast cancer treatment <sup>4</sup>								
Yes	350	31.6	-	-	269	32.7	-	-
No	756	68.4	-	-	553	67.3	-	-

Baseline characteristics of the responders and non-responders of the first COVID-19 wave may differ from previously published results [8], as clinical data were routinely updated by the Netherlands Cancer Registry, and the number of responses to the first COVID-19-specific survey increased after analyzing the first responses (due to the timely subject, only responses received before April 24, 2020 were used for analyses in our previous publication [8]).

As a result of rounding, percentages may not add up a 100%.

Abbreviations: *No.* Number; *SD* Standard deviation.

Legend: - Not applicable

<sup>1</sup> Calculated as weight/height<sup>2</sup>.

<sup>2</sup> Pre- and/ or postoperative therapy.

<sup>3</sup> Combination of chemotherapy, endocrine therapy and/or immunotherapy.

<sup>4</sup> Active treatment is defined as receiving chemotherapy, endocrine therapy, immunotherapy and/or radiation therapy at the time of completing the COVID-19-specific survey.